NCT02425735

Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

γδ T Cell Immunotherapy for Treatment of Hepatocellular Liver Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this study, effects of γδT cells on human hepatocellular liver cancer in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Detailed description

Liver tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.

Conditions

• Liver Cancer

Interventions

Type	Name	Description
BIOLOGICAL	DC-CIK cells	DC-CIK cells will be used against tumor cells.
BIOLOGICAL	γδ T cells	γδ T cells will be used against breast tumor.
BIOLOGICAL	γδ T/DC-CIK cells	γδ T/DC-CIK cells will be used against breast tumor.

Timeline

• Start date: 2015-04-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2015-04-24
• Last updated: 2016-07-19

Locations

1 site across 1 country: China